ArticleFrontiers in medicine2025
Epidemiological analysis of maternal hypertensive disorders of pregnancy.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum Pancreatic Stone Protein Across the Spectrum of Hypertensive Disorders of Pregnancy: Discrimination of Preeclampsia Compared with Conventional Inflammatory Indices.Medicina (Kaunas, Lithuania) · 2026Article
- 24-hour urinary total protein quantitative detection for pregnant women with unit conversion failure: a case report and laboratory administration reflection.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to provide a comprehensive overview of the epidemiology of hypertensive disorders of pregnancy (HDP) from 1990 to 2021, examining incidence and trends across national, continental, and global levels. Methods: HDP were assessed by calculating the age-standardized incidence rate (ASIR), age-standardized disability-adjusted life years (DALYs) rate, and the estimated annual percentage change (EAPC) for each region and country. The Global Burden of Disease (GBD) 2021 Study age-standardized rates, which were obtained from 204 countries and territories, were used to analyze the burden based on age and sociodemographic index (SDI). Results: The global burden of HDP has changed substantially between 1990 and 2021. The total number of DALYs was 2.47 million (95% UI: 2.08 to 2.96), and the ASIR was 461.94 per 100,000 in 2021. The estimated annual percentage change (EAPC) for the DALY rate was -2.10 (95% CI: -2.15 to -2.04), and the EAPC for ASIR was -0.51 (95% CI: -0.56 to -0.45). The Russian Federation, Romania, and Georgia had the greatest increases in ASIR over time. Guam, American Samoa, and the United Republic of Tanzania had the highest EAPC for the DALY rate. Analysis by age showed that maternal hypertensive disorders caused the highest DALYs among women aged 25-39 years and the lowest DALYs among those aged 50-54 years. There was a positive relationship between ASIR and SDI. The same trend was observed for the DALY rate. Conclusion: Our findings revealed that DALY rates and incidence rates of HDP decreased in most regions, except in areas with lower sociodemographic indices, such as the Caribbean. The greatest burden of HDP was observed among women aged 25-39 years. These results underscore the need for targeted interventions in low-SDI regions and highlight the importance of addressing HDP as a key component of maternal health initiatives globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.